BRIEF published on 01/16/2025 at 14:11, 10 months 19 days ago First Berlin Equity Research Initiates 'Buy' Rating for Medigene AG Immuno-oncology Stock Rating Biotech Partnerships Medigene AG TCR Therapies
BRIEF published on 01/16/2025 at 14:11, 10 months 19 days ago First Berlin Equity Research émet une note « Acheter » pour Medigene AG Immuno-oncologie Notation Des Actions Partenariats En Biotechnologie Medigene SA Thérapies TCR
PRESS RELEASE published on 01/16/2025 at 14:06, 10 months 19 days ago Original-Research: Medigene AG (von First Berlin Equity Research GmbH): Buy First Berlin Equity Research initiates coverage on Medigene AG with a Buy rating and €3.80 price target, highlighting the company's focus on developing T cell receptor-guided cancer therapies First Berlin Equity Research BUY Rating Medigene AG TCR-guided Therapies €3.80 Price Target
Published on 12/05/2025 at 02:35, 4 hours 4 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 5 hours 39 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 7 hours 34 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 7 hours 39 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 03:30, 3 hours 9 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 6 hours 49 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 10 hours 14 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 10 hours 24 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 11 hours 29 minutes ago SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance
Published on 12/04/2025 at 18:14, 12 hours 25 minutes ago Résiliation d'une convention conclue entre actionnaires
Published on 12/04/2025 at 18:00, 12 hours 39 minutes ago Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025
Published on 12/04/2025 at 18:00, 12 hours 39 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 12 hours 54 minutes ago Informations relatives au nombre total de droits de vote et d’actions
Published on 12/04/2025 at 17:45, 12 hours 54 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
